TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Status:
Completed
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the superiority of CHF 5993 100/6/12.5 µg pMDI
(fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus
glycopyrronum bromide) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine
beclometasone dipropionate plus formoterol fumarate), in terms of lung functions parameters
and rate of exacerbations, as well as to assess its safety and some health economics
outcomes.